報價延遲最少15分鐘:2024/11/10 18:14 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
36.61 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
0.09/1.09
|
|
企業價值
2.04B
|
| 資產負債 |
|
每股賬面淨值
17.38
|
| 現金流量 |
|
現金流量率
0.08
|
| 損益表 |
|
收益
607.52M
|
|
每股收益
11.08
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/11/10 18:14 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia inPD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER. |